Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – HER2 protein and gene expression predict the response of breast cancer patients to adjuvant trastuzumab therapy, but which test provides the best information?…
NEW YORK (Reuters Health) – Rates of clearance of high-grade anal canal intraepithelial neoplasia in men with HIV are improved considerably by topical application of imiquimod cream, a…
NEW YORK (Reuters Health) – Men undergoing androgen deprivation therapy for prostate cancer halve their risk of vertebral fractures if they take the selective estrogen receptor modulator toremifene…
NEW YORK (Reuters Health) – A Canadian study has identified several readily available clinical factors that help determine the risk of fractures in men with prostate cancer undergoing…
NEW YORK (Reuters Health) – The intensity of bortezomib-based regimens used to treat multiple myeloma in elderly patents can be reduced in order to lessen toxicity, without jeopardizing…
NEW YORK (Reuters Health) – Among adult patients being treated for hematologic malignancies and who are at high risk for tumor lysis syndrome with hyperuricemia, intravenous rasburicase does…
NEW YORK (Reuters Health) – Perioperative dexamethasone does not boost the risk of post-tonsillectomy hemorrhage, according to a large retrospective study reported in the August Archives of Otolaryngology…
NEW YORK (Reuters Health) – Women with a finding of atypical glandular cells (AGC) on cervical cytology are more likely than those without AGC to have malignant breast…
NEW YORK (Reuters Health) – After induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia (CLL), consolidation therapy with the monoclonal anti-CD52 antibody alemtuzumab (Campath-1H) improved…
NEW YORK (Reuters Health) – Concerns that bisphosphonate drugs used to treat osteoporosis might increase the risk of developing esophageal cancer have been put to rest by a…
